Abstract: Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis. Despite recent advances in prostate cancer treatment, some patients still experience recurrence or even progression after undergoing radical treatment. Accurate initial staging and monitoring for recurrence determine patient management, which in turn affect patient prognosis and survival. Classical imaging has limitations in the diagnosis and treatment of prostate cancer, but the use of novel molecular probes has improved the detection rate, specificity, and accuracy of prostate cancer detection. Molecular probe-based imaging modalities allow the visualization and quantitative measurement of biological processes at the molecular and cellular levels in living systems. An increased understanding of tumor biology of prostate cancer and the discovery of new tumor biomarkers have allowed the exploration of additional molecular probe targets. The development of novel ligands and advances in nano-based delivery technologies have accelerated the research and development of molecular probes. Here, we summarize the use of molecular probes in positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), optical imaging, and ultrasound imaging, and provide a brief overview of important target molecules in prostate cancer.

前列腺癌精确诊断与治疗的分子成像探针技术的研究进展

[1]AdamsJY,JohnsonM,SatoM,et al.,2002.Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging.Nat Med,8(8):891-896.

[2]AnY,ChangW,WangW,et al.,2020.A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn²⁺ in healthy versus cancerous cells.J Adv Res,24:363-370.

[3]AsanoY,InoueY,IkedaY,et al.,2011.Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogueanti-[¹⁸F]FACBC.Ann Nucl Med,25(6):414-418.

[4]AsimM,MassieCE,OrafidiyaF,et al.,2016.Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target.J Natl Cancer Inst,108(5):djv371.

[5]BaiJW,QiuSQ,ZhangGJ,2023.Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.Signal Transduct Target Ther,8:89.

[6]BanerjeeSR,KumarV,LisokA,et al.,2019.Evaluation of¹¹¹In-DOTA-5D3, a surrogate SPECT imaging agent for radioimmunotherapy of prostate-specific membrane antigen.J Nucl Med,60(3):400-406.

[7]BarattoL,JadvarH,IagaruA,2018.Prostate cancer theranostics targeting gastrin-releasing peptide receptors.Mol Imaging Biol,20(4):501-509.

[8]BasuS,HessS,Nielsen BraadPE,et al.,2014.The basic principles of FDG-PET/CT imaging.PET Clin,9(4):355-370.

[9]BeattieBJ,Smith-JonesPM,JhanwarYS,et al.,2010.Pharmacokinetic assessment of the uptake of 16β-¹⁸F-fluoro-5α-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.J Nucl Med,51(2):183-192.

[10]BénardF,HarsiniS,WilsonD,et al.,2022.Intra-individual comparison of¹⁸F-sodium fluoride PET-CT and^99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.Lancet Oncol,23(12):1499-1507.

[11]BhatnagarA,WangYC,MeaseRC,et al.,2014.AEG-1 promoter-mediated imaging of prostate cancer.Cancer Res,74(20):5772-5781.

[12]BiancoFJ,ScardinoPT,EasthamJA,2005.Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”).Urology,66(5Suppl):83-94.

[13]BostwickDG,PacelliA,BluteM,et al.,1998.Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.Cancer,82(11):2256-2261.

[14]BrawleyOW,2012.Trends in prostate cancer in the United States.J Natl Cancer Inst Monogr,2012(45):152-156.

[15]CalaisJ,CaoMS,NickolsNG,2018.The utility of PET/CT in the planning of external radiation therapy for prostate cancer.J Nucl Med,59(4):557-567.

[16]ChampagneA,JainP,VélotL,et al.,2022.A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy.Theranostics,12(2):474-492.

[17]ChandekarKR,SinghH,KumarR,et al.,2023.Comparison of¹⁸F-PSMA-1007 PET/CT with⁶⁸Ga-PSMA-11 PET/CT for initial staging in intermediate- and high-risk prostate cancer.Clin Nucl Med,48(1):e1-e8.

[18]ChatalicKL,Veldhoven-ZweistraJ,BolkesteinM,et al.,2015.A novel ¹¹¹In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT/CT imaging of prostate cancer.J Nucl Med,56(7):1094-1099.

[19]ChenYN,XuCD,ZhangZY,et al.,2021.Prostate cancer identification via photoacoustic spectroscopy and machine learning.Photoacoustics,23:100280.

[20]ChengLY,YangTS,ZhangJ,et al.,2023.The application of radiolabeled targeted molecular probes for the diagnosis and treatment of prostate cancer.Korean J Radiol,24(6):574-589.

[21]CombesAD,PalmaCA,CalopedosR,et al.,2022.PSMA PET-CT in the diagnosis and staging of prostate cancer.Diagnostics (Basel),12(11):2594.

[22]CookGJR,WongWL,SangheraB,et al.,2023.Eligibility for¹⁷⁷Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of⁶⁸Ga-PSMA-11 and^99mTc-MIP-1404 in metastatic castration-resistant prostate cancer.J Nucl Med,64(2):227-231.

[23]CooperbergMR,BroeringJM,CarrollPR,2010.Time trends and local variation in primary treatment of localized prostate cancer.J Clin Oncol,28(7):1117-1123.

[24]CrișanG,Moldovean-CioroianuNS,TimaruDG,et al.,2022.Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade.Int J Mol Sci,23(9):5023.

[25]Dell'OglioP,MeershoekP,MaurerT,et al.,2021.A DROP-IN gamma probe for robot-assisted radioguided surgery of lymph nodes during radical prostatectomy.Eur Urol,79(1):124-132.

[26]de VincentisG,GerritsenW,GschwendJE,et al.,2019.Advances in targeted alpha therapy for prostate cancer.Ann Oncol,30(11):1728-1739.

[27]DmochowskaN,MilanovaV,MukkamalaR,et al.,2023.Nanoparticles targeted to fibroblast activation protein outperform PSMA for MRI delineation of primary prostate tumors.Small,19(21):2204956.

[28]DongSL,WangYH,LiuZQ,et al.,2020.Beehive-inspired macroporous SERS probe for cancer detection through capturing and analyzing exosomes in plasma.ACS Appl Mater Interfaces,12(4):5136-5146.

[29]DongYZ,ZhouHY,AlhaskawiA,et al.,2023.The superiority of fibroblast activation protein inhibitor (FAPI) PET/CT versus FDG PET/CT in the diagnosis of various malignancies.Cancers (Basel),15(4):1193.

[30]DorfingerJ,PonholzerA,StolzlechnerM,et al.,2022.MRI/ultrasound fusion biopsy of the prostate compared to systematic prostate biopsy—effectiveness and accuracy of a combined approach in daily clinical practice.Eur J Radiol,154:110432.

[31]EderAC,OmraneMA,StadlbauerS,et al.,2021.The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging.Eur J Nucl Med Mol Imaging,48(6):2057-2058.

[32]EffertP,BeniersAJ,TamimiY,et al.,2004.Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma.Anticancer Res,24(5A):3057-3063.

[33]EisenhauerEA,TherasseP,BogaertsJ,et al.,2009.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer,45(2):228-247.

[34]EvazalipourM,D'HuyvetterM,TehraniBS,et al.,2014.Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.Contrast Media Mol Imaging,9(3):211-220.

[35]FanKL,CaoCQ,PanYX,et al.,2012.Magnetoferritin nanoparticles for targeting and visualizing tumour tissues.Nat Nanotechnol,7(7):459-464.

[36]FerroM,de CobelliO,VartolomeiMD,et al.,2021.Prostate cancer radiogenomics-from imaging to molecular characterization.Int J Mol Sci,22(18):9971.

[37]FilippiL,BagniO,CrisafulliC,et al.,2022.Detection rate and clinical impact of PET/CT with¹⁸F-FACBC in patients with biochemical recurrence of prostate cancer: a retrospective bicentric study.Biomedicines,10(1):177.

[38]FortuinA,van AstenJ,VeltienA,et al.,2023.Small suspicious lymph nodes detected on ultrahigh-field magnetic resonance imaging (MRI) in patients with prostate cancer with high risk of nodal metastases: the first in-patient study on ultrasmall superparamagnetic iron oxide-enhanced 7T MRI.Eur Urol,83(4):375-377.

[39]FortuinAS,BrüggemannR,van der LindenJ,et al.,2018.Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block.WIREs Nanomed Nanobiotechnol,10(1):e1471.

[40]FosbølMØ,KurbegovicS,JohannesenHH,et al.,2021.Urokinase-type plasminogen activator receptor (uPAR) PET/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with gleason score in a prospective phase 2 clinical trial.J Nucl Med,62(3):354-359.

[41]GaiYK,YuanLJ,SunLY,et al.,2020.Comparison of Al¹⁸F- and⁶⁸Ga-labeled NOTA-PEG₄-LLP2A for PET imaging of very late antigen-4 in melanoma.J Biol Inorg Chem,25(1):99-108.

[42]García-PérezFO,DavanzoJ,López-BuenrostroS,et al.,2018.Head to head comparison performance of^99mTc-EDDA/HYNIC-iPSMA SPECT/CT and⁶⁸Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.Am J Nucl Med Mol Imaging,8(5):332-340.

[43]GieselFL,HadaschikB,CardinaleJ,et al.,2017.F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.Eur J Nucl Med Mol Imaging,44(4):678-688.

[44]GondoputroW,ScheltemaMJ,BlazevskiA,et al.,2022.Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer.J Nucl Med,63(11):1659-1664.

[45]GroverVPB,TognarelliJM,CrosseyMME,et al.,2015.Magnetic resonance imaging: principles and techniques: lessons for clinicians.J Clin Exp Hepatol,5(3):246-255.

[46]HeYD,XuWD,XiaoYT,et al.,2022.Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.Signal Transduct Target Ther,7:198.

[47]HeesakkersRAM,FüttererJJ,HövelsAM,et al.,2006.Prostate cancer evaluated with ferumoxtran-10‒enhanced T2*-weighted MR imaging at 1.5 and 3.0 T: early experience. Radiology,239(2):481-487.

[48]HegdeJV,MulkernRV,PanychLP,et al.,2013.Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.J Magn Reson Imaging,37(5):1035-1054.

[49]HernotS,KlibanovAL,2008.Microbubbles in ultrasound-triggered drug and gene delivery.Adv Drug Deliv Rev,60(10):1153-1166.

[50]HernotS,van ManenL,DebieP,et al.,2019.Latest developments in molecular tracers for fluorescence image-guided cancer surgery.Lancet Oncol,20(7):e354-e367.

[51]HintzHM,GallantJP,Vander GriendDJ,et al.,2020.Imaging fibroblast activation protein alpha improves diagnosis of metastatic prostate cancer with positron emission tomography.Clin Cancer Res,26(18):4882-4891.

[52]HongSH,SunY,TangC,et al.,2017.Chelator-free and biocompatible melanin nanoplatform with facile-loading gadolinium and copper-64 for bioimaging.Bioconjugate Chem,28(7):1925-1930.

[53]HopeTA,EiberM,ArmstrongWR,et al.,2021.Diagnostic accuracy of⁶⁸Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial.JAMA Oncol,7(11):1635-1642.

[54]HricakH,ChoykePL,EberhardtSC,et al.,2007.Imaging prostate cancer: a multidisciplinary perspective.Radiology,243(1):28-53.

[55]HuangYT,TsengNC,ChenYK,et al.,2022.The detection performance of¹⁸F-prostate-specific membrane antigen-1007 PET/CT in primary prostate cancer: a systemic review and meta-analysis.Clin Nucl Med,47(9):755-762.

[56]IsikEG,Has-SimsekD,SanliO,et al.,2022.Fibroblast activation protein‒targeted PET imaging of metastatic castration-resistant prostate cancer compared with ⁶⁸Ga-PSMA and¹⁸F-FDG PET/CT.Clin Nucl Med,47(1):e54-e55.

[57]IsraelO,PelletO,BiassoniL,et al.,2019.Two decades of SPECT/CT ‒ the coming of age of a technology: an updated review of literature evidence. Eur J Nucl Med Mol Imaging,46(10):1990-2012.

[58]JadvarH,2011.Prostate cancer: PET with¹⁸F-FDG,¹⁸F- or¹¹C-acetate, and¹⁸F- or¹¹C-choline.J Nucl Med,52(1):81-89.

[59]JadvarH,2012.Molecular imaging of prostate cancer: PET radiotracers.Am J Roentgenol,199(2):278-291.

[60]JermynM,MokK,MercierJ,et al.,2015.Intraoperative brain cancer detection with Raman spectroscopy in humans.Sci Transl Med,7(274):274ra19.

[61]KaskovaZM,TsarkovaAS,YampolskyIV,2016.1001 lights: luciferins, luciferases, their mechanisms of action and applications in chemical analysis, biology and medicine.Chem Soc Rev,45(21):6048-6077.

[62]KinoshitaY,KuratsukuriK,LandasS,et al.,2006.Expression of prostate-specific membrane antigen in normal and malignant human tissues.World J Surg,30(4):628-636.

[63]KnipperS,Mehdi IraiM,SimonR,et al.,2023.Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery.Eur Urol,83(1):62-69.

[64]KothapalliSR,SonnGA,ChoeJW,et al.,2019.Simultaneous transrectal ultrasound and photoacoustic human prostate imaging.Sci Transl Med,11(507):eaav2169.

[65]KratochwilC,FlechsigP,LindnerT,et al.,2019.⁶⁸Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer.J Nucl Med,60(6):801-805.

[66]KularatneSA,ThomasM,MyersCH,et al.,2019.Evaluation of novel prostate-specific membrane antigen-targeted near-infrared imaging agent for fluorescence-guided surgery of prostate cancer.Clin Cancer Res,25(1):177-187.

[67]KumarR,SinghSK,MittalBR,et al.,2022.Safety and diagnostic yield of⁶⁸Ga prostate-specific membrane antigen PET/CT-guided robotic-assisted transgluteal prostatic biopsy.Radiology,303(2):392-398.

[68]KutenJ,FahoumI,SavinZ,et al.,2020.Head-to-head comparison of⁶⁸Ga-PSMA-11 with¹⁸F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard.J Nucl Med,61(4):527-532.

[69]LaudicellaR,AlbanoD,AlongiP,et al.,2019.¹⁸F-FACBC in prostate cancer: a systematic review and meta-analysis.Cancers (Basel),11(9):1348.

[70]LawalIO,AnkrahAO,MokgoroNP,et al.,2017.Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT.Prostate,77(11):1205-1212.

[71]LawalIO,MarcusC,SchusterDM,et al.,2023.Impact of¹⁸F-fluciclovine PET/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy.Clin Nucl Med,48(4):e153-e159.

[72]LeeC,JeonM,KimC,2015.Photoacoustic imaging in nanomedicine. In: Hamblin MR, Avci P (Eds.),Applications of Nanoscience in Photomedicine.Woodhead Publishing,Cambridge, p.31-47.

[73]LiSH,LiQ,ChenW,et al.,2022.A renal-clearable activatable molecular probe for fluoro-photacoustic and radioactive imaging of cancer biomarkers.Small,18(28):2201334.

[74]LindenbergL,AhlmanM,TurkbeyB,et al.,2016.Evaluation of prostate cancer with PET/MRI.J Nucl Med,57(Suppl 3):111S-116S.

[75]LindenbergL,MenaE,TurkbeyB,et al.,2020.Evaluating biochemically recurrent prostate cancer: histologic validation of¹⁸F-DCFPyL PET/CT with comparison to multiparametric MRI.Radiology,296(3):564-572.

[76]LiuF,QiL,LiuB,et al.,2015.Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis.PLoS ONE,10(3):e0116683.

[77]LiuX,JiangT,GaoCL,et al.,2022.Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: a systematic review and meta-analysis.Front Oncol,12:911146.

[78]MachedaML,RogersS,BestJD,2005.Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.J Cell Physiol,202(3):654-662.

[79]MansiR,FleischmannA,MäckeHR,et al.,2013.Targeting GRPR in urological cancers—from basic research to clinical application.Nat Rev Urol,10(4):235-244.

[80]MarcusC,Abiodun-OjoOA,JaniAB,et al.,2021.Clinical utility of¹⁸F-fluciclovine PET/CT in recurrent prostate cancer with very low (≤0.3 ng/mL) prostate-specific antigen levels.Am J Nucl Med Mol Imaging,11(5):406-414.

[81]MaurerT,EiberM,SchwaigerM,et al.,2016.Current use of PSMA-PET in prostate cancer management.Nat Rev Urol,13(4):226-235.

[82]MeaseRC,KangCM,KumarV,et al.,2022.An improved²¹¹At-labeled agent for PSMA-targeted α-therapy.J Nucl Med,63(2):259-267.

[83]MenaE,BlackPC,Rais-BahramiS,et al.,2021.Novel PET imaging methods for prostate cancer.World J Urol,39(3):687-699.

[84]MengZY,ZhangY,ShenE,et al.,2021.Marriage of virus-mimic surface topology and microbubble-assisted ultrasound for enhanced intratumor accumulation and improved cancer theranostics.Adv Sci (Weinh),8(13):2004670.

[85]MillerET,SalmasiA,ReiterRE,2018.Anatomic and molecular imaging in prostate cancer.Cold Spring Harb Perspect Med,8(3):a030619.

[86]NanniC,SchiavinaR,BrunocillaE,et al.,2015.¹⁸F-fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to¹¹C-choline PET/CT.Clin Nucl Med,40(8):e386-e391.

[87]NesslerI,KheraE,VanceS,et al.,2020.Increased tumor penetration of single-domain antibody-drug conjugates improvesin vivo efficacy in prostate cancer models.Cancer Res,80(6):1268-1278.

[88]O'KeefeDS,SuSL,BacichDJ,et al.,1998.Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene.Biochim Biophys Acta,1443(1-2):113-127.

[89]O'SullivanJM,NormanAR,CookGJ,et al.,2003.Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital.BJU Int,92(7):685-689.

[90]PapagiannopoulouD,2017.Technetium-99m radiochemistry for pharmaceutical applications.J Labelled Comp Radiopharm,60(11):502-520.

[91]ParkerC,CastroE,FizaziK,et al.,2020.Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol,31(9):1119-1134.

[92]PathmanandavelS,CrumbakerM,NguyenA,et al.,2023.The prognostic value of posttreatment⁶⁸Ga-PSMA-11 PET/CT and¹⁸F-FDG PET/CT in metastatic castration-resistant prostate cancer treated with¹⁷⁷Lu-PSMA-617 and NOX66 in a phase I/II trial (LuPIN).J Nucl Med,64(1):69-74.

[93]PeltierA,SebanRD,BuvatI,et al.,2022.Fibroblast heterogeneity in solid tumors: from single cell analysis to whole-body imaging.Semin Cancer Biol,86:262-272.

[94]PereraM,PapaN,ChristidisD,et al.,2016.Sensitivity, specificity, and predictors of positive⁶⁸Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis.Eur Urol,70(6):926-937.

[95]PereraRH,de LeonA,WangXN,et al.,2020.Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles.Nanomed Nanotechnol Biol Med,28:102213.

[96]PernthalerB,KulnikR,GstettnerC,et al.,2019.A prospective head-to-head comparison of¹⁸F-fluciclovine with⁶⁸Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT.Clin Nucl Med,44(10):e566-e573.

[97]PerssonM,SkovgaardD,Brandt-LarsenM,et al.,2015.First-in-human uPAR PET: imaging of cancer aggressiveness.Theranostics,5(12):1303-1316.

[98]PetersenLJ,ZachoHD,2020.PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.Cancer Imaging,20:10.

[99]PrasadV,SteffenIG,DiederichsG,et al.,2016.Biodistribution of [⁶⁸Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions.Mol Imaging Biol,18(3):428-436.

[100]RamyaAN,JosephMM,NairJB,et al.,2016.New insight of tetraphenylethylene-based Raman signatures for targeted SERS nanoprobe construction toward prostate cancer cell detection.ACS Appl Mater Interfaces,8(16):10220-10225.

[101]RatainMJ,EckhardtSG,2004.Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.J Clin Oncol,22(22):4442-4445.

[102]RathkopfDE,MorrisMJ,FoxJJ,et al.,2013.Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.J Clin Oncol,31(28):3525-3530.

[103]RenJY,YuanLL,WenGH,et al.,2016.The value of anti-1-amino-3-¹⁸F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.Acta Radiol,57(4):487-493.

[104]RossJS,SheehanCE,FisherHAG,et al.,2003.Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.Clin Cancer Res,9(17):6357-6362.

[105]RoweSP,PomperMG,2022.Molecular imaging in oncology: current impact and future directions.CA Cancer J Clin,72(4):333-352.

[106]Sadeghi-NainiA,FalouO,HudsonJM,et al.,2012.Imaging innovations for cancer therapy response monitoring.Imaging Med,4(3):311-327.

[107]Sanchez-CrespoA,2013.Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography.Appl Radiat Isot,76:55-62.

[108]SathianathenNJ,ButaneyM,KonetyBR,2019.The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.World J Urol,37(7):1239-1249.

[109]SchmuckS,MamachM,WilkeF,et al.,2017.Multiple time-point⁶⁸Ga-PSMA I&T PET/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging.Clin Nucl Med,42(6):e286-e293.

[110]SchollhammerR,RobertG,AsselineauJ,et al.,2023.Comparison of⁶⁸Ga-PSMA-617 PET/CT and⁶⁸Ga-RM2 PET/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study.J Nucl Med,64(3):379-385.

[111]SchotteliusM,WurzerA,WissmillerK,et al.,2019.Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer.J Nucl Med,60(1):71-78.

[112]SerkovaNJ,GlundeK,HaneyCR,et al.,2021.Preclinical applications of multi-platform imaging in animal models of cancer.Cancer Res,81(5):1189-1200.

[113]ShenCJ,MinnI,HobbsRF,et al.,2020.Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer.Theranostics,10(7):2888-2896.

[114]SilverDA,PellicerI,FairWR,et al.,1997.Prostate-specific membrane antigen expression in normal and malignant human tissues.Clin Cancer Res,3(1):81-85.

[115]SkovgaardD,PerssonM,Brandt-LarsenM,et al.,2017.Safety, dosimetry, and tumor detection ability of⁶⁸Ga-NOTA-AE105: first-in-human study of a novel radioligand for uPAR PET imaging.J Nucl Med,58(3):379-386.

[116]SodeeDB,MalguriaN,FaulhaberP,et al.,2000.Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer.Urology,56(6):988-993.

[117]SungH,FerlayJ,SiegelRL,et al.,2021.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin,71(3):209-249.

[118]TanY,FangZH,TangYX,et al.,2023.Clinical advancement of precision theranostics in prostate cancer.Front Oncol,13:1072510.

[119]TatarG,Baykal KocaS,Sevindirİ,et al.,2023.⁶⁸Ga-FAPI-04 PET/CT in primary signet ring-like cell carcinoma of prostate with bone metastases.Clin Nucl Med,48(4):e188-e189.

[120]TremblayS,AlhogbaniM,WeickhardtA,et al.,2023.Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial.Cancer Imaging,23:57.

[121]TurpinA,GirardE,BailletC,et al.,2020.Imaging for metastasis in prostate cancer: a review of the literature.Front Oncol,10:55.

[122]VahrmeijerAL,HuttemanM,van der VorstJR,et al.,2013.Image-guided cancer surgery using near-infrared fluorescence.Nat Rev Clin Oncol,10(9):507-518.

[123]VallabhajosulaS,NikolopoulouA,BabichJW,et al.,2014.^99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.J Nucl Med,55(11):1791-1798.

[124]VargasHA,WassbergC,FoxJJ,et al.,2014.Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.Radiology,271(1):220-229.

[125]VargasHA,KramerGM,ScottAM,et al.,2018.Reproducibility and repeatability of semiquantitative¹⁸F-fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: a prospective multicenter study.J Nucl Med,59(10):1516-1523.

[126]VarnosfaderaniZG,EmamzadehR,NazariM,et al.,2019.Detection of a prostate cancer cell line using a bioluminescent affiprobe: an attempt to develop a new molecular probe for ex vivo studies.Int J Biol Macromol,138:755-763.

[127]VasalouC,HelmlingerG,GomesB,2015.A mechanistic tumor penetration model to guide antibody drug conjugate design.PLoS ONE,10(3):e0118977.

[128]WangGC,HongHY,ZangJ,et al.,2022.Head-to-head comparison of [⁶⁸Ga]Ga-P16-093 and [⁶⁸Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients.Eur J Nucl Med Mol Imaging,49(3):1052-1062.

[129]WangR,ShenGH,HuangMX,et al.,2021.The diagnostic role of¹⁸F-choline,¹⁸F-fluciclovine and¹⁸F-PSMA PET/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis.Front Oncol,11:684629.

[130]WangY,de LeonAC,PereraR,et al.,2021.Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.Sci Rep,11:4726.

[131]WeisslederR,MahmoodU,2001.Molecular imaging.Radiology,219(2):316-333.

[132]WieserG,MansiR,GrosuAL,et al.,2014.Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist—from mice to men.Theranostics,4(4):412-419.

[133]XiaL,MengXX,WenL,et al.,2021.A highly specific multiple enhancement theranostic nanoprobe for PET/MRI/PAI image-guided radioisotope combined photothermal therapy in prostate cancer.Small,17(21):2100378.

[134]YinTH,WangK,QiuC,et al.,2020.Simple structural indocyanine green-loaded microbubbles for dual-modality imaging and multi-synergistic photothermal therapy in prostate cancer.Nanomed Nanotechnol Biol Med,28:102229.

[135]YouHJ,ShangWT,MinXD,et al.,2020.Sight and switch off: nerve density visualization for interventions targeting nerves in prostate cancer.Sci Adv,6(6):eaax6040.

[136]YuWX,ZhaoM,DengYJ,et al.,2023.Meta-analysis of¹⁸F-PSMA-1007 PET/CT,¹⁸F-FDG PET/CT, and⁶⁸Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer.Cancer Imaging,23(1):77.

[137]YuanM,WuY,ZhaoCY,et al.,2022.Activated molecular probes for enzyme recognition and detection.Theranostics,12(3):1459-1485.

[138]ZareH,RajabibazlM,RasooliI,et al.,2014.Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.Int J Biol Markers,29(2):169-179.

[139]ZhangJL,ChengDF,HeJY,et al.,2021.Cargo loading within ferritin nanocages in preparation for tumor-targeted delivery.Nat Protoc,16(10):4878-4896.

[140]ZhaoY,PengJ,YangJY,et al.,2019.Enhancing prostate-cancer-specific MRI by genetic amplified nanoparticle tumor homing.Adv Mater,31(30):1900928.